Asset
Envudeucitinib
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05600036 | phase2 | completed | 2022-09-27 | 2023-06-29 | Alumis Inc | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis |
| NCT06962774 | phase1 | completed | 2025-04-23 | 2025-08-01 | Alumis Inc | An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function |
| NCT07378579 | phase1 | completed | 2024-06-21 | 2024-08-31 | Alumis Inc | An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001 |
| NCT05953688 | phase2 | terminated | 2023-06-14 | 2024-08-13 | Alumis Inc | POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU |
| NCT05330858 | phase1 | completed | 2022-03-17 | 2022-06-30 | Alumis Inc | Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants |
FDA applications (0)
This company has no applications containing this asset.